Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers

Cancer Immunology, Immunotherapy

Volumn 57, Issue 9, 2008, Pages 1413-1420

  Toubaji, Antoun ^a,c   Achtar, Moujahed ^a   Provenzano, Maurizio ^a,d   Herrin, Vincent E ^b,e   Behrens, Robert ^a   Hamilton, Michael ^b,f   Bernstein, Sarah ^b   Venzon, David ^a   Gause, Barry ^b   Marincola, Francesco ^a   Khleif, Samir N ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^f Avalon Pharmaceuticals   (United States)

Author keywords

Adjuvant; Colorectal cancer; Immunotherapy; Mutant ras; Pancreatic cancer

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; LYSYLLEUCYLVALYLVALYLVALYLGLYCYLALANYLASPARTYLGLYCYLVALYLGLYCYL LYSYLSERINE; LYSYLLEUCYLVALYLVALYLVALYLGLYCYLALANYLCYSTEINYLGLYCYLVALYLGLYCYL LYSYLSERINE; LYSYLLEUCYLVALYLVALYLVALYLGLYCYLALANYLVALYLGLYCYLVALYLGLYCYLLYSYLSERINE; MESSENGER RNA; PHOSPHORYL LIPID A; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; HUMAN; IMMUNE RESPONSE; MALE; PANCREAS CANCER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; CANCER VACCINES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENES, RAS; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; PILOT PROJECTS;

EID: 45849097153     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0477-6     Document Type: Article

References (25)

1. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN et al (1993) K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143(2):545-554
2. Li ZH, Zheng J, Weiss LM, Shibata D (1994) c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am J Pathol 144(2):303-309
3. Breivik J, Meling GI, Spurkland A, Rognum TO, Gaudernack G (1994) K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br J Cancer 69(2):367-371
4. Weiss S, Bogen B (1991) MHC class II-restricted presentation of intracellular antigen. Cell 64(4):767-776
5. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC (1991) Identification of self peptides bound to purified HLA-B27. Nature 353(6342):326-329
6. Abrams SI, Stanziale SF, Lunin SD, Zaremba S, Schlom J (1996) Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses. Eur J Immunol 26(2):435-443
7. Fossum B, Gedde-Dahl T 3rd, Breivik J, Eriksen JA, Spurkland A, Thorsby E et al (1994) p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly → Asp). Int J Cancer 56(1):40-45
8. Fossum B, Olsen AC, Thorsby E, Gaudernack G (1995) CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly13 → Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol Immunother 40(3):165-172
9. Gedde-Dahl T 3rd, Fossum B, Eriksen JA, Thorsby E, Gaudernack G (1993) T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and HLA restriction. Eur J Immunol 23(3):754-760
10. Van Elsas A, Nijman HW, Van der Minne CE, Mourer JS, Kast WM, Melief CJ et al (1995) Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201. Int J Cancer 61(3):389-396
11. Abrams SI, Khleif SN, Bergmann-Leitner ES, Kantor JA, Chung Y, Hamilton JM et al (1997) Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Cell Immunol 182(2):137-151
12. Khleif SN, Abrams SI, Hamilton JM, Bergmann-Leitner E, Chen A, Bastian A et al (1999) A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother 22(2):155-165
13. Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Solheim BG, Soreide O et al (1995) Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 346(8987):1399-1400
14. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O et al (2001) Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92(3):441-450
15. Carbone DP, Ciernik IF, Kelley MJ, Smith MC, Nadaf S, Kavanaugh D et al (2005) Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol 23:5099-5107
16. Hsieh CL, Chen DS, Hwang LH (2000) Tumor-induced immunosuppression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine. Hum Gene Ther 11(5):681-692
17. Mocellin S, Wang E, Marincola FM (2001) Cytokines and immune response in the tumor microenvironment. J Immunother 24(5):392-407
18. Mocellin S, Rossi CR, Lise M, Marincola FM (2002) Adjuvant immunotherapy for solid tumors: from promise to clinical application. Cancer Immunol Immunother 51(11-12):583-595
19. Hoover HC Jr, Brandhorst JS, Peters LC, Surdyke MG, Takeshita Y, Madariaga J et al (1993) Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 11(3):390-399
20. Harris JE, Ryan L, Hoover HC Jr, Stuart RK, Oken MM, Benson AB 3rd et al (2000) Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern cooperative oncology group study E5283. J Clin Oncol 18(1):148-157
21. Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA et al (1999) Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 163(12):6867-6875
22. Rothman KJ (1978) Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chronic Dis 31(8):557-560
23. Provenzano M, Mocellin S, Bettinotti M, Preuss J, Monsurro V, Marincola FM et al (2002) Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells. J Immunother 25(4):342-351
24. Provenzano M, Mocellin S, Bonginelli P, Nagorsen D, Kwon SW, Stroncek D (2003) Ex vivo screening for immunodominant viral epitopes by quantitative real time polymerase chain reaction (qRT-PCR). J Transl Med 1(1):12
25. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR et al (2001) Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 19(1):145-156